Last reviewed 2026-04-23 · How we verify

Semaglutide(Wegovy® )

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels. Used for Chronic weight management in adults with obesity or overweight with at least one weight-related condition, Treatment of type 2 diabetes.

At a glance

Mechanism of action

By activating the GLP-1 receptor, semaglutide increases insulin secretion, decreases glucagon levels, and slows gastric emptying, leading to improved glycemic control and weight loss.

Approved indications

• Chronic weight management in adults with obesity or overweight with at least one weight-related condition
• Treatment of type 2 diabetes

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Injection site reactions

Key clinical trials

• Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
• A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults (PHASE1)
• A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
• Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
• JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity (PHASE4)
• A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
• A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
• The Effects of Semaglutide on Body Composition and Performance in Military Personnel (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.